Skip to main content
First page of PDF

Formats available

You can view the full content in the following formats:

References

1.
Agency for Healthcare Research and Quality. Glossary: underuse, overuse, misuse (2017). https://psnet.ahrq.gov/glossary/U
2.
Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch. Intern. Med. 170(9), 749–750 (2010).
3.
Warren JL, Klabunde CN, Mariotto AB et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann. Intern. Med. 150(12), 849–857 (2009).
4.
Zhang Y, Lee BY, Donohue JM. Ambulatory antibiotic use and prescription drug coverage in older adults. Arch. Intern. Med. 170(15), 1308–1314 (2010).
5.
de Souza JA, Conti RM. Mitigating financial toxicity among US patients with cancer. JAMA Oncol. 3(6), 765–766 (2017).
6.
Valero-Elizondo J, Khera R, Saxena A et al. Financial hardship from medical bills among nonelderly U.S. adults with atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 73(6), 727–732 (2019).
7.
Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA 307(14), 1513–1516 (2012).
8.
Mack JW, Cronin A, Keating NL et al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J. Clin. Oncol. 30(35), 4387–4395 (2012).
9.
Teno JM, Fisher E, Hamel MB et al. Decision-making and outcomes of prolonged ICU stays in seriously ill patients. J. Am. Geriatr. Soc. 48(S1), S70–S74 (2000).
10.
Ganguli I, Lupo C, Mainor AJ et al. Prevalence and cost of care cascades after low-value preoperative electrocardiogram for cataract surgery in fee-for-service Medicare beneficiaries. JAMA Intern. Med. (2019) (Epub ahead of print).
11.
Lucas FL, Siewers AE, Malenka DJ, Wennberg DE. Diagnostic-therapeutic cascade revisited: coronary angiography, coronary artery bypass graft surgery, and percutaneous coronary intervention in the modern era. Circulation 118(25), 2797–2802 (2008).
12.
Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin. Interv. Aging 3(2), 383–389 (2008).
13.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin. Drug Saf. 13(1), 57–65 (2014).
14.
Morgan DJ, Leppin AL, Smith CD, Korenstein D. A practical framework for understanding and reducing medical overuse: conceptualizing overuse through the patient–clinician interaction. J. Hosp. Med. 12(5), 346–351 (2017).
15.
Varadhan R, Segal JB, Boyd CM, Wu AW, Weiss CO. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J. Clin. Epidemiol. 66(8), 818–825 (2013).
16.
Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 298(10), 1209–1212 (2007).
17.
Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials 10, 43 (2009).
18.
Gabler NB, Duan N, Raneses E et al. No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals. Trials 17(1), 320 (2016).
19.
Lavelle TA, Kent DM, Lundquist CM et al. Patient variability seldom assessed in cost–effectiveness studies. Med. Decis. Making 38(4), 487–494 (2018).
20.
Brooks JM, Fang G. Interpreting treatment-effect estimates with heterogeneity and choice: simulation model results. Clin. Ther. 31(4), 902–919 (2009).